EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieMultizentrische StudieVergleichsstudieOpen Access

Sequential Enzalutamide–Docetaxel Versus Abiraterone–Docetaxel Therapy in Castration‐Resistant Prostate Cancer: A Subanalysis of the ENABLE Study

Manabu Kamiyama iD, Kouji Izumi iD, Takahiko Mitsui iD, Takashi Shima, Yuki Kato iD, Koji Mita iD, Takehiko Okamura iD, Shogo Inoue iD, Seiji Hoshi iD, Nobumichi Tanaka iD, Yuko Yoshio, Shuichi Tatarano iD und 7 weitere

International Journal of Urology · 2026

DOI: 10.1111/iju.70599 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift International Journal of Urology, 2026. Verfasst von Manabu Kamiyama und 18 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo, Yamanashi, Japan. Hauptthemen laut MEDLINE: Prostatic Neoplasms, Castration-Resistant, Docetaxel, Phenylthiohydantoin, Androstenes. Die Arbeit nennt 25 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: The Japanese Foundation for Multidisciplinary Treatment of Cancer..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

Docetaxel (DTX) is commonly employed in patients with castration‐resistant prostate cancer (CRPC) following failure of androgen receptor signaling inhibitors (ARSIs). However, the impact of prior ARSI treatment on the efficacy of subsequent DTX therapy remains unclear. This study aimed to compare oncological outcomes between enzalutamide (ENZ)–DTX and abiraterone acetate plus prednisolone (ABI)–DTX sequential treatment strategies in patients with CRPC.

Methods

The ENABLE study for PCa was an investigator‐initiated, multicenter, randomized controlled trial conducted in Japan to compare ENZ and ABI. This subanalysis evaluated the efficacy of subsequent DTX therapy in patients who had received either ENZ or ABI.

Results

Between February 2015 and July 2019, 203 patients were enrolled, of whom 184 were randomized to receive ENZ or ABI (92 per arm). Among them, 20 and 21 patients subsequently initiated DTX therapy following ENZ and ABI, respectively. Median prostate cancer‐specific survival (PCSS) in the ENZ–DTX and ABI–DTX groups was 22.7 and 32.1 months, respectively ( p = 0.1724). Median PCSS from the initiation of DTX was 16.1 months in the ENZ–DTX group and 25.3 months in the ABI–DTX group ( p = 0.0966). In the overall cohort ( n = 41), patients who received additional ARSIs after ARSI–DTX therapy had significantly longer PCSS from the initiation of DTX compared with those who did not (median 21.6 vs. 13.8 months, p = 0.0157).

Conclusions

ENZ–DTX and ABI–DTX sequential therapies demonstrated comparable survival outcomes in patients with CRPC. Notably, the administration of additional ARSIs following ARSI–DTX therapy may confer a survival benefit, suggesting a potential role for continued ARSI use in this treatment sequence. Trial Registration The trial was registered with the University Hospital Medical Information Network (UMIN) Center under the identifier UMIN000015529 on November 1, 2014

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Prostatic Neoplasms, Castration-ResistantDocetaxelPhenylthiohydantoinAndrostenesAntineoplastic Combined Chemotherapy ProtocolsMaleHumansBenzamidesNitrilesAgedJapanAged, 80 and overPrednisoloneMiddle AgedTreatment Outcome

Stichwörter der Autor:innen

abirateronedocetaxelenzalutamidesequential therapysurvival

Substanzen

BenzamidesenzalutamideDocetaxelNitrilesPhenylthiohydantoinAndrostenesabirateronePrednisolone

Autor:innen und Institutionen

  • Department of Urology, University of Yamanashi Graduate School of Medical Sciences, Chuo, Yamanashi, Japan.
  • Department of Integrative Cancer Therapy and Urology, Kanazawa University Graduate School of Medical Science, Kanazawa, Ishikawa, Japan.
  • Department of Urology, Toyama Prefectural Central Hospital, Toyama, Japan.
  • Department of Urology, Fukui-Ken Saiseikai Hospital, Fukui, Fukui, Japan.
  • Department of Urology, Hiroshima City North Medical Center Asa Citizens Hospital, Hiroshima, Hiroshima, Japan.
  • Department of Urology, Anjo Kosei Hospital, Anjo, Aichi, Japan.

ORCID-Profile: Manabu Kamiyama, Kouji Izumi, Takahiko Mitsui, Yuki Kato, Koji Mita, Takehiko Okamura, Shogo Inoue, Seiji Hoshi, Nobumichi Tanaka, Shuichi Tatarano, Noriyasu Kawai, Kohei Hashimoto, Takashi Fukagai, Kazuyoshi Shigehara, Atsushi Mizokami

Förderung

  • The Japanese Foundation for Multidisciplinary Treatment of Cancer.

Zitieren

APA

Kamiyama, M., Izumi, K., Mitsui, T., Shima, T., Kato, Y., Mita, K., Okamura, T., Inoue, S., Hoshi, S., Tanaka, N., Yoshio, Y., Tatarano, S., Chikazawa, I., Kawai, N., Hashimoto, K., Fukagai, T., Shigehara, K., Takahara, S., & Mizokami, A. (2026). Sequential Enzalutamide–Docetaxel Versus Abiraterone–Docetaxel Therapy in Castration‐Resistant Prostate Cancer: A Subanalysis of the ENABLE Study. International Journal of Urology. https://doi.org/10.1111/iju.70599

Vancouver

Kamiyama M, Izumi K, Mitsui T, Shima T, Kato Y, Mita K, et al. Sequential Enzalutamide–Docetaxel Versus Abiraterone–Docetaxel Therapy in Castration‐Resistant Prostate Cancer: A Subanalysis of the ENABLE Study. International Journal of Urology. 2026. doi:10.1111/iju.70599

BibTeX
@article{Kamiyama2026,
  author = {Kamiyama, Manabu and Izumi, Kouji and Mitsui, Takahiko and Shima, Takashi and Kato, Yuki and Mita, Koji and Okamura, Takehiko and Inoue, Shogo and Hoshi, Seiji and Tanaka, Nobumichi and Yoshio, Yuko and Tatarano, Shuichi and Chikazawa, Ippei and Kawai, Noriyasu and Hashimoto, Kohei and Fukagai, Takashi and Shigehara, Kazuyoshi and Takahara, Shizuko and Mizokami, Atsushi},
  title = {Sequential Enzalutamide–Docetaxel Versus Abiraterone–Docetaxel Therapy in Castration‐Resistant Prostate Cancer: A Subanalysis of the ENABLE Study},
  journal = {International Journal of Urology},
  year = {2026},
  doi = {10.1111/iju.70599}
}
Kostenlos starten →